Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy

PURPOSE: The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear. We sought to determine the proportion...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Main Authors: Crespo, James, Sun, Hongxia, Wu, Jimin, Ding, Qing-Qing, Tang, Guilin, Robinson, Melissa K., Chen, Hui, Sahin, Aysegul A., Lim, Bora
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2020
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7660495/
https://ncbi.nlm.nih.gov/pubmed/33180796
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0241775
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares